retatrutide lab | Research Grade Peptide Retatrutide (Reta GLP-3) - 99%+

Metabolic adaptation during pregnancy serves an evolutionary purpose

Role of Breast Cancer Resistance Protein (BCRP/ABCG2) in Cancer Drug Resistance

You can read the full article at Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity The goal of the study was to find out how semaglutide encourages weight loss

Tirzepatide maintenance: the SURMOUNT-4 evidence The SURMOUNT-4 trial used a randomized-withdrawal design: all participants took open-label tirzepatide for 36 weeks (reaching a mean weight reduction of about 20.9%), then were randomized either to continue the drug or switch to placebo for another 52 weeks